Literature DB >> 1749826

Cytokines in Alzheimer's disease.

L D Altstiel1, K Sperber.   

Abstract

1. Human astrocytoma cells produced biologically active interleukin-6 when treated with a variety of agents including bacterial lipopolysaccharides, viruses, and interleukin-1. 2. Both human recombinant IL-6 and IL-6 produced by stimulated astrocytes promoted differentiation of cultured neuronal cells and reduced survival time in culture. 3. Interleukin-6 and interleukin-1 stimulated the synthesis of the Alzheimer's disease beta-amyloid precursor protein. 4. Cytokines may be involved in stimulation of dystrophic neuritic sprouting, neuronal death, and amyloid deposition noted in the brains of Alzheimer's disease patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1749826     DOI: 10.1016/0278-5846(91)90023-t

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  12 in total

Review 1.  Cognitive enhancement therapy for Alzheimer's disease. The way forward.

Authors:  L Parnetti; U Senin; P Mecocci
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

2.  Targeting the TLR4/NF-κΒ Axis and NLRP1/3 Inflammasomes by Rosuvastatin: A Role in Impeding Ovariectomy-Induced Cognitive Decline Neuropathology in Rats.

Authors:  Muhammed A Saad; Muhammad Y Al-Shorbagy; Hany H Arab
Journal:  Mol Neurobiol       Date:  2022-05-17       Impact factor: 5.590

3.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor.

Authors:  J D Buxbaum; M Oishi; H I Chen; R Pinkas-Kramarski; E A Jaffe; S E Gandy; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

4.  Serum cytokine levels in patients with Alzheimer's disease.

Authors:  C C Chao; T A Ala; S Hu; K B Crossley; R E Sherman; P K Peterson; W H Frey
Journal:  Clin Diagn Lab Immunol       Date:  1994-07

5.  Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients.

Authors:  M Huell; S Strauss; B Volk; M Berger; J Bauer
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

6.  Induction of aromatic L-amino acid decarboxylase mRNA by interleukin-1 beta and prostaglandin E2 in PC12 cells.

Authors:  X M Li; A V Juorio; A A Boulton
Journal:  Neurochem Res       Date:  1994-05       Impact factor: 3.996

Review 7.  Glial cytokines in Alzheimer's disease: review and pathogenic implications.

Authors:  R E Mrak; J G Sheng; W S Griffin
Journal:  Hum Pathol       Date:  1995-08       Impact factor: 3.466

8.  Transforming growth factor beta in Alzheimer's disease.

Authors:  C C Chao; S Hu; W H Frey; T A Ala; W W Tourtellotte; P K Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1994-01

9.  Luteolin alleviates cognitive impairment in Alzheimer's disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation.

Authors:  Jie-Jian Kou; Jun-Zhuo Shi; Yang-Yang He; Jiao-Jiao Hao; Hai-Yu Zhang; Dong-Mei Luo; Jun-Ke Song; Yi Yan; Xin-Mei Xie; Guan-Hua Du; Xiao-Bin Pang
Journal:  Acta Pharmacol Sin       Date:  2021-07-15       Impact factor: 6.150

Review 10.  Interleukin-6, a major cytokine in the central nervous system.

Authors:  María Erta; Albert Quintana; Juan Hidalgo
Journal:  Int J Biol Sci       Date:  2012-10-25       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.